Anti-Tumorgenic Impact of Nano-Formulated Peptide HIF-Alpha Therapy by DMBA Induced Mammary Carcinoma in Rodent Type

Abstract

Over the past decade, personalized medicine has acquired considerable attention, emerging as a promising avenue for enhancing cancer treatment and therapy. Within this rapidly increasing field, the latest research introduces an innovative approach focused on a nano-formulated peptide, HIF-alpha, distinguished by its unique dual pharmacological potential. Various tumor-induced rat model has been undertaken to assess the peptide's efficacy in combatting DMBA-induced breast cancer. The findings clearly demonstrate the synthesized peptide's profound impact on various feature of tumor biology, including the proliferation of malignant cells, the synthesis of fatty acids crucial for cellular metabolism, and the regulation of lactate levels implicated in tumor progression. Histopathological analyses provide compelling evidence of the peptide's ability to established multifaceted pharmacological effects within the tumor microenvironment. Moreover, it has been demonstrated that regulatory influence on key membrane receptors, namely HER2 and EGFR, further underscores its therapeutic promise. In summary, the peptide HIF-alpha emerges as a potential landmark, offering a more efficacious therapeutic adjunct to existing medications, irrespective of the malignancy's stage. This innovative discovery holds transformative potential in reshaping conventional cancer treatment paradigms, heralding a new era of precision medicine in oncology.